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Objectives: The aim of this study was to evaluate the cost-effectiveness in liver transplantation (LT) of
utilizing organs donated after cardiac death (DCD) compared with organs donated after brain death
(DBD).
Methods: A Markov-based decision analytic model was created to compare two LT waitlist strategies
distinguished by organ type: (i) DBD organs only, and (ii) DBD and DCD organs. The model simulated
outcomes for patients over 10 years with annual cycles through one of four health states: survival;
ischaemic cholangiopathy; retransplantation, and death. Baseline values and ranges were determined
from an extensive literature review. Sensitivity analyses tested model strength and parameter variability.
Results: Overall survival is decreased, and biliary complications and retransplantation are increased in
recipients of DCD livers. Recipients of DBD livers gained 5.6 quality-adjusted life years (QALYs) at a cost
of US$69 000/QALY, whereas recipients on the DBD + DCD LT waitlist gained 6.0 QALYs at a cost of
US$61 000/QALY. The DBD + DCD organ strategy was superior to the DBD organ-only strategy.
Conclusions: The extension of life and quality of life provided by DCD LT to patients on the waiting list
who might otherwise not receive a liver transplant makes the continued use of DCD livers cost-effective.
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Introduction
Liver transplantation (LT) is the treatment of choice in end-
stage liver disease. Despite the adoption of the Model for End-
stage Liver Disease (MELD) system of organ allocation, which
prioritizes those who are most ill or have hepatocellular carci-
noma (HCC), waitlist mortality has remained stable for many
years because the number of candidates for LT continues to rise,
but the number of organs available for transplant has reached a
plateau.1 As the gap between numbers of donor organs and LT
candidates continues to widen, strategies that maximize the use of
all available grafts while maintaining optimal outcomes are
required. From 1968, when criteria for establishing brain death
were developed, to the end of the 20th century, the only reliable
source of livers was derived from subjects who donated after brain
death (DBD).2 However, organs donated after cardiac death
(DCD) have now become widely accepted as an alternative source
of organs for transplant and the use of DCD organs has been
encouraged by the United Network for Organ Sharing. Although
the use of DCD organs has increased the number of potentially
available organs, questions about outcomes related to the use of
organs from cardiac death donors remain. These concerns have
tempered acceptance of the use of DCD organs in the USA, where
the proportion of LTs using DCD organs has plateaued at about
6% despite the lengthy candidate waitlist.3–5
Historically, both patient and graft survival in DCD LT have
been significantly lower than in DBD LT.3–16 Other adverse out-
comes, such as post-transplant acute kidney injury, hepatitis C
virus recurrence and biliary complications, have also been shown
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to be higher after DCD LT.7,8,10,15,17–21 Recently published data indi-
cate that outcomes following DCD LT may approach those of
DBD LT when there is careful attention to donor and recipient
selection and limited cold ischaemic time.14,21,22 Despite these
encouraging clinical findings, the potential financial burden and
societal benefits of DCD LT are unknown.
The current study sought to elucidate the cost-effectiveness,
from a societal perspective, of using DBD and DCD organs in LT.
The objective of this study was to develop a Markov model to
evaluate the cost-effectiveness, including potential outcomes,
associated costs and recipient quality of life, of incorporating two
different options for LT into waitlist management strategies that:
(i) limited potential recipients to receiving DBD organs only, or
(ii) allowed potential recipients to receive either DBD or DCD
organs. Results from this study may guide surgeons in decision
making for individual LT candidates, as well as informing policy
making and future planning.
Materials and methods
Markov decision model
The Markov decision analysis technique is used to model out-
comes for groups of hypothetical patients and to analyse time,
value and costs of patients in each state of health. Outcomes are
simulated for each hypothetical patient group over prespecified
time intervals or cycles. Initially, hypothetical patients are assigned
to a health state but can change health states each time the model
is cycled. An ‘absorbing state’ is a state, such as death, that the
patient cannot leave once it is entered. The model is run iteratively
either until all hypothetical patients have reached an absorbing
state or over a dictated time horizon (such as 10 years in the
present model). When the time horizon is limited, the model does
not run until all patients reach an absorbing state, but instead
stops when the predetermined time is complete. A comprehensive
literature review is used to determine the likelihood that, in any
model cycle, a patient will either remain in his or her current state
or transition to a new health state. A value, most commonly
expressed in quality-adjusted life year (QALY) units, is assigned to
a patient within a given health state. These values accumulate over
each cycle and the net valuation is calculated for each patient after
all cycles have been completed. The financial cost per value
(QALY) of each health state can be computed and compared with
the values of the other treatment strategies.23,24
A Markov-based decision analytic model was constructed to
simulate outcomes from a societal perspective for two different
waitlist strategies: (i) a strategy that limited potential recipients to
receiving DBD organs only, and (ii) an alternative approach that
permitted potential recipients to receive either DBD or DCD
organs. In this model, the determined cost for each type of donor
included the direct costs of transplantation to the hospital or the
payer, such as the costs of the procedure, materials and length of
hospitalization. Indirect costs of transplantation such as lost
earning potential of the recipient, out-of-hospital expenses and
the costs of immunosuppressants were also included.
TreeAge Pro 2010 (TreeAge Software, Inc., Williamstown, MA,
USA), software that is specifically designed to create and evaluate
decision trees and models, was used to construct and run the
model using methods similar to those reported previously by the
present group.25 The cost-effectiveness analysis was performed
and reported according to the Panel on Cost-Effectiveness in
Health and Medicine guidelines.26–27
Health states
The Markov decision model shown in Fig. 1 included two waitlist
strategies which: (i) limited potential recipients to receiving DBD
organs only, or (ii) allowed potential recipients to receive either
DBD or DCD organs. In each arm of the model, candidates were
placed on the waitlist and were then transplanted (or not trans-
planted) at different rates depending on the waitlist strategy.
Following LT, the hypothetical patient experienced one of the
following scenarios based on predetermined probabilities as
determined from the literature: uneventful recovery; ischaemic
cholangiopathy; retransplantation, or death.
Model assumptions
Several assumptions were made in the creation of this model. The
patient in the base case scenario was a 56-year-old man with
non-alcoholic steatohepatitis. All costs associated with LT were
assumed to be the same for both DBD and DCD LT. In addition,
for the DCD organ, all donor qualities, such as age and body mass
index (BMI), as well as procedure-related characteristics, such as
procurement techniques and warm and cold ischaemia time, were
not varied. Wait-listed candidates for both the DBD organ-only
and DBD + DCD organs were modelled to be identical. The
recipient pools for both DBD organ-only and DBD + DCD organs
were assumed to be homogeneous in terms of characteristics such
as age, MELD score and aetiology of liver failure distributions. All
retransplanted livers were modelled as DBD organs.
Probability and cost data
The probabilities and rates for the baseline analysis and the ranges
of these values for all sensitivity analyses are reported in Table 1.
These values were determined through a systematic review of the
MEDLINE/PubMed database for all reports on deceased donor LT
from 2000 to 2011, especially reviews of Scientific Registry of
Transplant Recipients (SRTR) data and meta-analyses. Table 1
also presents all cost estimates and ranges. Published data for
specific institutional costs, the Medicare database, or similar data-
bases were used for the cost analysis. Cost data were also obtained
from published studies identified in the systematic review of the
literature. All monetary values were adjusted for inflation to 2010
US dollars using the Consumer Price Index for medical care (US
Bureau of Labor Statistics28). To account for the cost of spending
money now vs. in the future, health benefits and future costs were
discounted at a constant rate of 3%.26
All costs were approached from a societal perspective.29 Mod-
elling from the societal perspective allows for comparisons with
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findings in similar studies that focus on patient outcomes and
costs to society. Both positive and negative cost changes resulting
from an intervention were considered. Furthermore, rather than
being limited to interpretation for a particular patient population,
the present findings can be interpreted from the public or societal
point of view.
Utilities
The effectiveness of different waitlist strategies was measured in
terms of QALYs. This measure of health value incorporates both
quality of life and time into a composite statistic that allows
for comparison between health interventions. Quality of life is
determined by health utilities reported in the literature, which
usually range from 0 (utility of death) to 1 (utility of perfect
health). Utilities represent the reported health preferences of
groups of patients in the various health states of the model30
(Table 1).
Sensitivity analysis
One- and two-way sensitivity analyses were performed to test the
model conclusions based on variations in the range of values and
costs reported in the literature. The ranges utilized for these
analyses are described in Table 1. Multi-way probabilistic
sensitivity analyses using Monte Carlo methods, which change
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Figure 1 Markov decision tree representing the choice of strategies for organ donation. The two clinical options are represented at the
decision node. Probabilities and estimates of probabilities are listed in Table 1. , choice between strategies (decision node); , occurrence
of chance events (chance node); , logic check in the simulation (terminal node). DBD, donated after brain death; DCD, donated after
cardiac death; ESLD, end-stage liver disease; OLT, orthotopic liver transplant
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all probabilities and costs within the model simultaneously,31
provided additional tests of model sensitivity to changes in model
parameters.
Results
Base case analysis
The previously described model assumptions and the base case
probabilities and costs from Table 1 were used in the base case
analysis. When the model is run, the program simulates the tran-
sition of hypothetical patients through the model. The results of
the reference case analysis in the Markov model are essentially the
averages associated with the different outcomes of these hypo-
thetical patients, and are listed in Table 2 and depicted graphically
in Fig. 2.
The base case patient in this model was a 56-year-old man with
non-alcoholic steatohepatitis. Five-year survival was modelled at
65% in recipients of DCD livers and 75% in recipients of DBD
livers. Using a 10-year time horizon, the waitlist strategy that relied
exclusively on DBD organs resulted in costs of US$386 000 to
achieve 5.6 QALYs, or approximately US$69 000/QALY. The wait-
list strategy that employed both DBD and DCD organs resulted in
costs of US$366 000 to achieve 6.0 QALYs, or approximately
US$61 000/QALY. Therefore, the DBD +DCD organ waitlist strat-
egy was superior to, and dominated, the DBD organ-only strategy.
Sensitivity analysis
Because the baseline probabilities and costs used in this model
vary among the centres and regions in which these procedures are
Table 1 Probabilities and costs based on reports in the literature
Baseline parameters Value Range References
3-year survival, % 3–16,20,32
DBD OLT 75% 50–90%
DCD OLT 65% 45–85%
Retransplantation 45% 35–75%
Probability of DCD organ 5% 3–20%
Retransplantation rate, % 3,6,7,9–16,18,20,33,34
DBD OLT 5% 2–8%
DCD OLT 15% 5–35%
Ischaemic cholangiopathy rate, % 7,8,17–22,28,34
DBD OLT 1% 0–5%
DCD OLT 20% 15–40%
Waitlist mortality, % 32,35–39
DBD organ-only list 15% 5–25%
DBD + DCD organ list 10% 5–25%
Utility 4,25,29,33,34,40–51
Cirrhosis on waitlist 0.6 QALY 0.3–0.8 QALY
OLT 0.8 QALY 0.5–0.9 QALY
Retransplantation 0.7 QALY 0.4–0.9 QALY
Ischaemic cholangiopathy 0.6 QALY 0.3–0.8 QALY
Cost, US$ 3,4,16,25,27,33,34,41–54
Waitlist death 50 000 25 000–75 000
OLT 150 000 100 000–200 000
Retransplantation 200 000 150 000–250 000
Ischaemic cholangiopathy 30 000 15 000–50 000
DBD, donated after brain death; DCD, donated after cardiac death; OLT, orthotopic liver transplant; QALY, quality-adjusted life year.
Table 2 Costs and cost-effectiveness of donated organs
Strategy Cost, US$ Incremental
cost, US$
Effectiveness Incremental
effectiveness
Cost-effectiveness,
US$
DBD + DCD organs 366 000 – 6.0 QALYs – 61 100/QALY
DBD organs only 386 000 18 000 5.6 QALYs -0.450 QALY 69 300/QALY
DBD, donated after brain death; DCD, donated after cardiac death; QALY, quality-adjusted life year.
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performed, one- and two-way sensitivity analyses were conducted
to test the validity of the conclusions over a range of probabilities
and costs. Figure 3 demonstrates the results of a one-way sensi-
tivity analysis in which the rate of waitlist survival in the DBD
organ-only strategy is varied. Annual rates of survival on the
waitlist vary between 50% and 99%. The threshold value at which
DBD + DCD organ use is no longer the dominant (superior)
strategy is 93%. Therefore, if waitlist mortality is <7%, the use of
only DBD organs becomes the preferable strategy. Figure 4 dem-
onstrates the results of a one-way sensitivity analysis in which the
annual rate of survival after DCD LT is varied. The threshold value
at which DBD + DCD organ use is no longer the dominant strat-
egy is 83%. Therefore, the DBD organ-only strategy becomes pref-
erable if annual mortality after DCD LT exceeds 17%. Figure 5
demonstrates the results of a one-way sensitivity analysis in which
the probability of retransplantation after DCD LT is varied. The
threshold value at which the DBD + DCD LT strategy no longer
dominates is 21%, which means the DBD organ-only strategy is
preferable if the retransplantation rate after DCD LT exceeds 21%.
In Fig. 6, the probability of receiving a DBD organ in the DBD +
DCD LT strategy is varied. When the rate of DBD organs reaches
a threshold value of 90%, the DBD organ strategy dominates.
Therefore, if DCD organs represent >10% of the donor organ
pool, the DBD + DCD waitlist strategy is no longer preferable. In
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Figure 2 Results of the base case analysis in the Markov model
comparing the cost-effectiveness of liver transplantation in end-
stage liver disease using organs donated after brain death (DBD) and
donated after cardiac death (DCD). The DBD + DCD organ strategy
was superior to the DBD organ-only strategy. OLT, orthotopic liver
transplant; QALY, quality-adjusted life year
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Figure 3 One-way sensitivity analysis in which the rate of waitlist
death is varied in the strategy utilizing only organs donated after
brain death (DBD). When waitlist mortality is <7% for those awaiting
DBD organs only, this becomes the preferable strategy. DCD,
donated after cardiac death; OLT, orthotopic liver transplant; QALY,
quality-adjusted life year
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Figure 4 One-way sensitivity analysis in which yearly survival after
transplant utilizing organs donated after cardiac death (DCD) is
varied. The strategy utilizing only organs donated after brain death
(DBD) is the better strategy when the annual mortality rate after DCD
organ transplant exceeds 17%. OLT, orthotopic liver transplant;
QALY, quality-adjusted life year
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Figure 5 One-way sensitivity analysis in which the probability of
retransplantation in the strategy using organs donated after brain
death (DBD) and organs donated after cardiac death (DCD) is varied.
The DBD organs-only strategy is preferable if retransplantation after
DCD liver transplantation exceeds 21%. OLT, orthotopic liver trans-
plant; QALY, quality-adjusted life year
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two-way sensitivity analyses in Fig. 7, rates of waitlist survival in
the DBD organ-only strategy and annual post-transplant survival
after DCD LT are varied simultaneously. The DBD organ-only
transplant strategy becomes dominant at very low rates of DBD
organ-only waitlist death and very high rates of post-DCD LT
mortality.
One- and two-way sensitivity analyses were performed for a
variety of ranges for costs and utilities; the DBD + DCD organ
waitlist was the dominant strategy at all clinically relevant values.
Additionally, multi-way probabilistic sensitivity analyses using
Monte Carlo methods indicated that DBD + DCD LT was the
preferable strategy at all clinically relevant values.
Discussion
Donation after cardiac death is a reasonable solution to address, in
part, the well-recognized shortage of organs. The provision of
DCD organs can expand the potential donor organ pool by as
much as 20%. Outcomes following LT with DBD organs are typi-
cally reported as being better than those of LT with DCD livers;
however, recent publications indicate that careful pairing of
recipients with DCD organs and optimized procurement and
transplant procedures may narrow this disparity.14,21,22 The aim of
this study was to evaluate the cost-effectiveness of a waitlist strat-
egy that included the use of both DCD and DBD organs compared
with one that relied on DBD organs exclusively. The present analy-
ses indicated that, although the modelled 3-year survival in DCD
LT was less than that in DBD LT, the improvement in waitlist
survival and quality of life that occurred when DCD organs were
included in a waitlist strategy made their use cost-effective. Sen-
sitivity analyses demonstrated that the use of both DBD and DCD
organs continued to be cost-effective as long as DCD organs did
not account for >10% of the organs transplanted and the retrans-
plantation rate after DCD LT did not exceed 21%. At most US
transplant centres, rates of use of DCD organs and retransplan-
tation fall within these parameters.
According to the present model, individual patients who
received a DCD liver had a decreased 3-year modelled survival.
Decreased patient survival has also been reported by other
groups in both single-centre reports4,6,11,14,15 and in a recent
review of Scientific Registry of Transplant Recipients (SRTR)
data by Jay et al.11 Similarly, Mathur and colleagues’ review of
SRTR data demonstrated that increased donor age, donor weight
and cold ischaemia time were associated with poor outcomes.14
There is substantial variability in reported rates of biliary com-
plications and graft failure associated with DCD LT. The present
model indicates that individual patients receiving organs from
cardiac death donors encounters a three-fold increase in biliary
complications in comparison with patients who receive a liver
from a brain death donor. These findings are consistent with those
of previously published reports.1,7,9,15,19 Foley and colleagues
reported single-centre overall rates of biliary complications of
47% in recipients of DCD organs and 26% in those receiving DBD
organs.8 DeOliveira and colleagues reported a recent European
experience of lower overall rates of biliary complications, but
noted that higher rates persisted among patients receiving DCD
organs (19.7%) in comparison with those receiving DBD organs
(12.5%).7
In head-to-head comparisons of costs associated with DBD and
DCD LT, DCD LT is usually shown to incur higher costs for
transplant procedures and post-transplant care. For example,
recent analyses of data from the UK demonstrated an increased
cost of GBP97 400 per LT when the organ was sourced from a
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cardiac death donor, largely as a result of an increased hospital
length of stay and rates of acute renal failure requiring inpatient
dialysis.4,5 In the present model, the cost per QALY gained by using
organs from the DCD + DBD organ pool was lower than the
equivalent cost in the DBD organ-only strategy. By contrast with
the UK analyses,4,5 the present model evaluated the costs and
benefits in a cohort of hypothetical waitlist patients from a societal
perspective, rather than an individual patient perspective. The
decreased cost per QALY gained in the DBD + DCD LT strategy
results from the inclusion of more potential donors in the donor
pool. The costs are lower in this donor strategy because of the
decreases in waitlist mortality and pre-transplant morbidity asso-
ciated with an increased number of donors.
The present cost-utility model provides a new and necessary
perspective on societal-level implications of the use of DCD organs
in LT. Increasingly, health care cost minimization considerations
are balanced with outcome optimization to determine the best
options for providing health care at the lowest cost. From the
societal perspective, recipients in the DBD + DCD organ waitlist
group gained, on average, more QALYs at a lower average cost per
QALY in comparison with those in the DBD organs-only group.
A limitation of this study is that LT and donor type consider-
ations have been distilled into a very basic model. The authors
recognize that transplant outcomes depend on several recipient
characteristics and procedural factors that are not accounted for
in the current model. Future studies might include separate
models of the use of DCD organs in select recipient populations
incorporating pertinent clinical factors such as cold ischaemia
time, warm ischaemia time, MELD score, age, and donor and
recipient BMI, to model the complexity of DCD LT outcomes.
The present study used published data and meta-analyses to
approximate the most likely clinical scenarios, probabilities and
costs associated with different types of organ sources. Any publi-
cation bias that exists in the peer-reviewed literature on this topic
would therefore be reflected in the present model estimates.
A strength of the cost-effectiveness model is that it is adaptable
to a wide range of clinical scenarios. The current model helps to
elucidate factors that contribute to determining the optimal eco-
nomic strategy for LT in the face of a substantial disparity between
the numbers of candidates and donors. It provides data that can
inform future discussions at the patient, institutional and societal
levels. Additionally, in an era of increasing health care costs, this
model allows policymakers to further understand the costs asso-
ciated with various options of organ source and utilization in LT
and helps to identify policies that are most likely to optimize
patient care and minimize societal costs.
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